Durvalumab Plus Olaparib vs Durvalumab Alone as Maintenance Therapy for Metastatic NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Durvalumab in Combination with Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study
J Thorac Oncol 2023 Jun 28;[EPub Ahead of Print], MJ Ahn, I Bondarenko, E Kalinka, BC Cho, S Sugawara, G Gálffy, BY Shim, N Kislov, R Nagarkar, I Demedts, SJM Gans, D Mendoza Oliva, R Stewart, Z Lai, H Mann, X Shi, M HusseinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.